Emergence of an MDR Klebsiella pneumoniae ST231 producing OXA-232 and RmtF in Switzerland

Stefano Mancini1,3*, Laurent Poiret1,3, Marie-Lise Tritten3, Reto Lienhard4, Cécile Bassi5 and Patrice Nordmann1,3,6

1Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland; 2INSERM European Unit, LEA/IAME Paris, France; 3Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland; 4ADMED Microbiologie, 2300 La Chaux-de-Fonds, Switzerland; 5Médecine Interne, Hôpital du Jura Bernois, 2610 St-Imier, Switzerland; 6Institute of Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland

*Corresponding author. Medical and Molecular Microbiology, University of Fribourg, CH-1700 Fribourg, Switzerland. Tel: +41 26 300 9583; E-mail: stefano.mancini@unifr.ch

Sir,

The increasing incidence of carbapenem-resistant Klebsiella pneumoniae is a major challenge to public health. Despite the fact that the prevalence of carbapenemases among carbapenem-resistant K. pneumoniae varies geographically, the incidence of OXA-48-like enzymes has soared in recent years and is particularly high in some European countries, such as Spain and France (74% and 78% among carbapenemase-producing K. pneumoniae, respectively).1 A significant number of OXA-48 variants have been reported in the last decade. This includes OXA-232, a carbapenemase firstly identified in France in 20111 and thereafter found in several countries.2–4 Recently, an MDR K. pneumoniae ST231 co-producing OXA-232, the ESBL CTX-M-15 and the 16S RNA methyltransferase RmtF conferring broad-spectrum resistance to aminoglycosides has emerged as a successful epidemic clone in South-East Asia, with related outbreaks being reported in Singapore and in Brunei Darussalam between 2013 and 2015.5,6 Here, we report on a nosocomial spread of this emerging resistant strain in Switzerland.

Six K. pneumoniae clinical isolates with reduced susceptibility or resistant to carbapenems were recovered from February to April 2017 from five different patients, namely three hospitalized in the medicine ward of a regional hospital in Western Switzerland, and two non-hospitalized at the private Ear, Nose and Throat (ENT) centre located near to the hospital (Table 1) and were sent to the Swiss National Reference Center for Emerging Antibiotic Resistance for further characterization. All the patients reported no recent travel abroad. Clinical and epidemiological analyses failed to detect any obvious route of transmission for those isolates.

Antimicrobial susceptibility testing was performed by disc diffusion assay (Sanofi-diagnostic Pasteur, France) and MICs were determined using Etest (bioMérieux, France) and broth microdilution techniques, with susceptibility defined according to CLSI breakpoints (https://clsi.org/standards/products/microbiology/documented/m100/). Four isolates were resistant to penicillins, broad-spectrum cephalosporins, meropenem and ertapenem and showed intermediate resistance to imipenem. The remaining two isolates displayed a typical ESBL phenotype, with resistance towards all penicillins, to expanded-spectrum cephalosporins (antagonized by β-lactamase inhibitors) and to ertapenem, and susceptibility to imipenem and meropenem. Interestingly, one isolate presenting carbapenemase activity and one exhibiting an ESBL phenotype had been recovered from a single patient (Table 1). All six K. pneumoniae isolates also exhibited broad-spectrum resistance to aminoglycosides and were additionally resistant to sulphonamides, fluoroquinolones, trimethoprim/sulfamethoxazole, chloramphenicol, tetracycline and to the recently developed ceftolozane/tazobactam combination. Notably, all six clinical isolates were susceptible to colistin and to the ceftazidime/avibactam combination.

Multiplex PCRs performed to detect Ambler class A, B and D carbapenemases and 16S rRNA aminoglycoside resistance genes7,8 followed by sequencing revealed that all six isolates possessed the rmtF 16S RNA methyltransferase gene, and that the four carbapenem-resistant isolates possessed the blaOXA-232 carbapenemase gene. In addition, all the isolates possessed the ESBL blaCTX-M-15 and the blaTEM-1 gene (Table 1). Transferability of the blaOXA-232, blaCTX-M-15 and rmtF genes was attempted by mating-out assays using the azide-resistant Escherichia coli J53 as a recipient strain. Transconjugants were obtained on azide (100 mg/L) and either amikacin/gentamicin (50 mg/L each) or ceftazidime (1 mg/L), but not imipenem (1 mg/L), indicating the transferability of the plasmids harbouring the rmtF and blaCTX-M-15, but not that one carrying the blaOXA-232 gene. Analysis of the plasmid content by using the Kieser technique revealed the presence of several plasmids in all isolates. The blaOXA-232 was carried on a 6141 bp plasmid identical to that identified by Potron et al.,9 as further supported by sequence analysis performed as previously reported.6 Notably, the rmtF and blaCTX-M-15 genes were located on the same 160 kb plasmid. PFGE of the SpeI-digested genomic DNA obtained from the six K. pneumoniae isolates revealed that they were clonally related. MLST showed that they belonged to ST231 (https://cge.cbs.dtu.dk/services/MLST/).

In an attempt to unravel the genetic factors contributing to the emergence and spread of this multiresistant pathogen, WGS of genomic DNA from isolate Kp1 (KP06–2017) was performed using a MiSeq system (Illumina, USA), generating a total of 13 078 950 reads with an average length of 145.8 bp. Reads were de novo assembled using CLC Genomics Workbench version 7.5.1 (Qiagen, France). The draft genome revealed a size of 6 015 778 bp, with an average GC content of approximately 57%. The antimicrobial resistance gene was identified using ResFinder10 and comprises genes...
conferring resistance to aminoglycosides (rmtF, aadB, aadA2 and aacA4), β-lactams (blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B), fluoroquinolones [aac(6′)-Ib-cr], macrolides, lincosamides and streptogramin B (MLS) [erm(B) and mph(A)], phenicols (catA1 and catB4), sulphonamides (sul1), trimethoprim (dfrA12) and rifampicin (arr-2) (Table 1). Plasmid finder\(^\text{10}\) revealed the presence of IncFIB(pQil), aacA4, blalones [B(MLS)], two present in the plasmids carrying the IncFII(K), IncFII(pRSB107), IncFIA and ColKP3 replicons; the latter is present in the plasmids carrying the rmtF, Tem, OXA-232, CTX-M-15 and blaOXA-232 genes, respectively.

Overall, to our knowledge, we report here the first occurrence in Europe of an MDR K. pneumoniae ST231 clone, so far geographically confined in South-East Asia. This represents an important and worrying step toward the rise of another epidemic clone as a global public threat.

**Accession number**

The draft genome sequence of the *K. pneumoniae* KP06–2017 has been deposited in GenBank under accession number NTFP00000000.

**Funding**

This work was funded by the University of Fribourg, by the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) and by the Swiss National Science Foundation (project FNS-31003A_163432).

**Transparency declarations**

None to declare.

---

**Table 1. Characteristics of the Klebsiella pneumoniae isolates under study**

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Ward</th>
<th>Specimen</th>
<th>Date of isolation</th>
<th>ST</th>
<th>β-Lactamases identified by PCR</th>
<th>Approximate sizes of plasmids (kbp)</th>
<th>carbapenems</th>
<th>MIC (mg/L)</th>
<th>novel cephalosporin/β-lactamase inhibitor combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kp1</td>
<td>ENT</td>
<td>sinus swab</td>
<td>28/02/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 6.1, 9, 70, 160</td>
<td>2</td>
<td>&gt;256</td>
<td>&gt;256, 2</td>
</tr>
<tr>
<td>Kp2</td>
<td>ENT</td>
<td>sinus swab</td>
<td>09/03/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 6.1, 9, 70, 160</td>
<td>2</td>
<td>&gt;256</td>
<td>&gt;256, 2</td>
</tr>
<tr>
<td>Kp3</td>
<td>Medicine</td>
<td>urine</td>
<td>21/03/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 4.8, 9, 70, 160</td>
<td>0.38</td>
<td>0.25</td>
<td>&gt;256, 2</td>
</tr>
<tr>
<td>Kp4</td>
<td>Medicine</td>
<td>rectal swab</td>
<td>23/03/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 6.1, 9, 70, 160</td>
<td>2</td>
<td>&gt;256</td>
<td>&gt;256, 2</td>
</tr>
<tr>
<td>Kp5</td>
<td>Medicine</td>
<td>rectal swab</td>
<td>29/03/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 4.8, 9, 70, 160</td>
<td>0.38</td>
<td>0.25</td>
<td>&gt;256, 2</td>
</tr>
<tr>
<td>Kp6</td>
<td>Medicine</td>
<td>rectal swab</td>
<td>10/04/17</td>
<td>231</td>
<td>blaOXA-232, blaOXA-CTX-M-15, blaTEM-1B</td>
<td>3.6, 6.1, 9, 70, 160</td>
<td>2</td>
<td>&gt;256</td>
<td>&gt;256, 2</td>
</tr>
</tbody>
</table>

IPM, imipenem; MEM, meropenem; ETP, ertapenem.

**References**


---